Literature DB >> 35614365

Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab.

Marina Di Pino1, Maria Filomena Ruberto1, Giulia Costanzo1, Davide Firinu2, Maria Sebastiana Piras1, Mario Nicola Mura1, Stefano Del Giacco1, Ferdinando Coghe1, Francesco Marongiu1, Doris Barcellona1.   

Abstract

Chronic spontaneous urticaria (CSU) is a disorder characterized by wheals and/or angioedema. The coagulation cascade and inflammation pathways are closely linked together. The aim of our study was first to investigate the dynamics of clot formation in plasma (Clot Waveform Analysis, CWA) in a group of 47 patients with CSU along with other coagulative parameters dedicated to the study of hypercoagulability, such as D-Dimer, F 1 + 2 peptide, Fibrinogen, Platelet count and Mean Platelet Volume (MPV). Secondly, 23 out of 47 patients were treated with Omalizumab at four administration intervals from T0 to T4. A statistically significant increase in Activated Partial Thromboplastin (aPTT) ratio, D-Dimer, F1 + 2, Platelet count and MPV was found when compared with 53 healthy controls (HC). In contrast, the 2nd Derivative of aPTT showed lower values than those of the HC. No differences were found between 1st derivative of aPTT and Fibrinogen. D-Dimer only showed a significant difference between T0 and T3. An activation of both coagulation and fibrinolysis along with a weaker clot acceleration may be in agreement with a low-grade DIC. The accelerated turnover of platelets expressed by both an increase in platelet count and MPV further supports this pathway in CSU. Omalizumab does not affect the relationship between the immune and the hemostatic systems.
© 2022. The Author(s).

Entities:  

Keywords:  Chronic spontaneous urticaria; Clot waveform analysis; D-Dimer; Endogenous thrombin generation; Omalizumab treatment

Year:  2022        PMID: 35614365     DOI: 10.1007/s10238-022-00838-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  23 in total

1.  A study of atypical APTT derivative curves on the ACL TOP coagulation analyser.

Authors:  C Solano; P Zerafa; R Bird
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

Review 2.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.

Authors:  Massimo Cugno; Angelo V Marzano; Riccardo Asero; Alberto Tedeschi
Journal:  Intern Emerg Med       Date:  2009-12-01       Impact factor: 3.397

Review 3.  Omalizumab for the treatment of chronic urticaria.

Authors:  Torsten Zuberbier; Marcus Maurer
Journal:  Expert Rev Clin Immunol       Date:  2015-01-07       Impact factor: 4.473

4.  Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.

Authors:  Ioana Agache; Claudio Rocha; Ana Pereira; Yang Song; Pablo Alonso-Coello; Ivan Solà; Jessica Beltran; Margarita Posso; Cezmi A Akdis; Mubeccel Akdis; Knut Brockow; Tomas Chivato; Stefano Del Giacco; Thomas Eiwegger; Kilian Eyerich; Ana Giménez-Arnau; Jan Gutermuth; Emma Guttman-Yassky; Marcus Maurer; Graham Ogg; Peck Ong; Liam O'Mahony; Jürgen Schwarze; Thomas Werfel; Carlos Canelo-Aybar; Oscar Palomares; Marek Jutel
Journal:  Allergy       Date:  2020-09-07       Impact factor: 13.146

5.  Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Hong-Xia Jia; Yan-Ling He
Journal:  Am J Ther       Date:  2020 Sep/Oct       Impact factor: 2.688

6.  The venous thromboembolic risk and the clot wave analysis: a useful relationship?

Authors:  Maria Filomena Ruberto; Francesco Marongiu; Antonella Mandas; Antonella Mameli; Mariagrazia Porru; Elisabetta Cianchetti; Doris Barcellona
Journal:  Clin Chem Lab Med       Date:  2018-02-23       Impact factor: 3.694

7.  The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.

Authors:  T Zuberbier; W Aberer; R Asero; A H Abdul Latiff; D Baker; B Ballmer-Weber; J A Bernstein; C Bindslev-Jensen; Z Brzoza; R Buense Bedrikow; G W Canonica; M K Church; T Craig; I V Danilycheva; C Dressler; L F Ensina; A Giménez-Arnau; K Godse; M Gonçalo; C Grattan; J Hebert; M Hide; A Kaplan; A Kapp; C H Katelaris; E Kocatürk; K Kulthanan; D Larenas-Linnemann; T A Leslie; M Magerl; P Mathelier-Fusade; R Y Meshkova; M Metz; A Nast; E Nettis; H Oude-Elberink; S Rosumeck; S S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; P Staubach; G Sussman; E Toubi; G A Vena; C Vestergaard; B Wedi; R N Werner; Z Zhao; M Maurer
Journal:  Allergy       Date:  2018-07       Impact factor: 13.146

8.  Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?

Authors:  Maria F Ruberto; Francesco Marongiu; Orazio Sorbello; Alberto Civolani; Luigi Demelia; Doris Barcellona
Journal:  Int J Lab Hematol       Date:  2018-10-09       Impact factor: 2.877

9.  The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Authors:  M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2017-07-10       Impact factor: 13.146

Review 10.  The coagulation system in host defense.

Authors:  Silvio Antoniak
Journal:  Res Pract Thromb Haemost       Date:  2018-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.